{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:43:31Z","timestamp":1793375011550,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamacardio.2019.0179","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T15:11:20Z","timestamp":1551885080000},"page":"314","source":"Crossref","is-referenced-by-count":120,"title":["Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome"],"prefix":"10.1001","volume":"4","author":[{"given":"Preethi","family":"Mani","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Puri","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Veterans Affairs Medical Center and University of Colorado, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Shao","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"},{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"MonashHeart, Monash University, Clayton, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"hoi190006r1","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"issue":"15","key":"hoi190006r2","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"20","key":"hoi190006r3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa021993","article-title":"Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.","volume":"347","author":"Ridker","year":"2002","journal-title":"N Engl J Med"},{"issue":"25","key":"hoi190006r4","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1056\/NEJMoa040967","article-title":"Inflammatory markers and the risk of coronary heart disease in men and women.","volume":"351","author":"Pai","year":"2004","journal-title":"N Engl J Med"},{"issue":"9050","key":"hoi190006r5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S0140-6736(96)07591-5","article-title":"Production of C-reactive protein and risk of coronary events in stable and unstable angina.","volume":"349","author":"Haverkate","year":"1997","journal-title":"Lancet"},{"issue":"26","key":"hoi190006r6","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi190006r7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy.","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"12","key":"hoi190006r8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi190006r9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S0002-9149(01)02190-7","article-title":"Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction.","volume":"89","author":"Zebrack","year":"2002","journal-title":"Am J Cardiol"},{"issue":"7","key":"hoi190006r10","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/S0735-1097(98)00136-3","article-title":"C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction.","volume":"31","author":"Morrow","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi190006r11","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","article-title":"Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.","volume":"311","author":"Nicholls","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"hoi190006r13","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/hrt.47.3.239","article-title":"Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction.","volume":"47","author":"de Beer","year":"1982","journal-title":"Br Heart J"},{"issue":"13","key":"hoi190006r14","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.","volume":"108","author":"Kinlay","year":"2003","journal-title":"Circulation"},{"issue":"3","key":"hoi190006r15","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ahj.2004.07.041","article-title":"Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study.","volume":"149","author":"Macin","year":"2005","journal-title":"Am Heart J"},{"issue":"8","key":"hoi190006r16","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0735-1097(01)01289-X","article-title":"Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebo-controlled study using a highly sensitive C-reactive protein assay.","volume":"37","author":"Feldman","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hoi190006r17","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1161\/01.CIR.100.8.793","article-title":"Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.","volume":"100","author":"Ikonomidis","year":"1999","journal-title":"Circulation"},{"issue":"11","key":"hoi190006r18","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/jth.2004.2.issue-11","article-title":"A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial.","volume":"2","author":"Woodward","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"3","key":"hoi190006r19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.amjcard.2004.04.035","article-title":"Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.","volume":"94","author":"Vivekananthan","year":"2004","journal-title":"Am J Cardiol"},{"issue":"10118","key":"hoi190006r20","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"hoi190006r21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/hrt.2007.118794","article-title":"Evaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortality.","volume":"94","author":"Currie","year":"2008","journal-title":"Heart"},{"issue":"2","key":"hoi190006r22","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ahj.2015.04.017","article-title":"Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality.","volume":"170","author":"Parrinello","year":"2015","journal-title":"Am Heart J"},{"issue":"1","key":"hoi190006r23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/hh1301.093825","article-title":"Tissue factor, the emerging link between inflammation, thrombosis, and vascular remodeling.","volume":"89","author":"Penn","year":"2001","journal-title":"Circ Res"},{"issue":"13","key":"hoi190006r24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1161\/01.CIR.103.13.1718","article-title":"Inflammation and thrombosis: the clot thickens.","volume":"103","author":"Libby","year":"2001","journal-title":"Circulation"},{"key":"hoi190006r12","volume-title":"Counting Processes and Survival Analysis","author":"Fleming","year":"2013"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamacardiology\/article-pdf\/4\/4\/314\/17483825\/jamacardiology_mani_2019_oi_190006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T16:02:16Z","timestamp":1555516936000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2019.0179"}},"subtitle":["A Secondary Analysis of the VISTA-16 Trial"],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.0179","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}